More than 50 patients are pursuing legal action over the use of faulty Zimmer NexGen knee implants that have been linked to severe pain, limited mobility, and dependence on pain medication. These implants, which were recalled in December 2022, exhibited failure rates reportedly up to five times higher than other comparable devices.

Initial concerns about the implants emerged in 2015 when the National Joint Registry detected early failures in the tibial component of the Zimmer NexGen system. Despite these warnings, the implants continued to be used for several years, resulting in hundreds of patients undergoing revision surgeries to correct or replace the faulty devices. Each revision procedure imposes a significant financial burden on the National Health Service (NHS), with estimated costs ranging between £10,000 and £30,000 per surgery.

Lawyers specializing in medical negligence at Irwin Mitchell have already filed 24 cases in the High Court related to these implants and are appealing to other affected patients to come forward. One of the claimants, 80-year-old Lydia Osborne, reported enduring persistent pain and difficulty walking following her knee replacement surgery with a Zimmer NexGen implant.

Zimmer Biomet, the manufacturer, maintains that the majority of patients experienced positive results from the implants but acknowledged the decision to withdraw the problematic tibial component from the market. The company has emphasized its commitment to patient safety and ongoing investigation into the device’s performance.

A forthcoming hearing at the High Court, scheduled for next spring, will address the subsequent stages of this legal matter, potentially shaping the response to claims stemming from the defective knee implants.